{
    "2020-01-15": [
        [
            {
                "time": "",
                "original_text": "大摩：喜好业务模式更具抵抗力的企业 均予药明生物(02269)及药明康德(02359)“增持”评级",
                "features": {
                    "keywords": [
                        "大摩",
                        "药明生物",
                        "药明康德",
                        "增持",
                        "业务模式",
                        "抵抗力"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "多因素共振，未来三年医药外包将迎来投资机会",
                "features": {
                    "keywords": [
                        "多因素共振",
                        "医药外包",
                        "投资机会",
                        "未来三年"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}